Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa trial of YKYY015 injection in adults with elevated LDL-C
ChiCTR2600116277Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of YKYY015 in hypercholesterolemia and combined dyslipidaemia (4 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Percentage change in low-density lipoprotein cholesterol from baseline, Incidence and severity of adverse events and 4 more. Started Jan 2026; status: recruiting.
02
Drugs
YKYY015
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on ChiCTR2600116277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116277.